All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Professor Kieron Dunleavy is a Professor of Medicine, Director of the Lymphoma Program and Co-Director of the Microbial Oncology Program in the Division of Hematology & Oncology at The George Washington University Cancer Center, Washington D.C., US. Prof. Dunleavy was educated at University College Dublin, Dublin, IE, and subsequently at the National Cancer Institute (NCI), Bethesda, US. Following his fellowship at the NCI, he remained on staff as an attending physician and has been the Clinical Director of the Lymphoid Malignancies Branch at the NCI. Prof. Dunleavy’s work to date has focused on the biology and treatment of lymphoid diseases. His interests include aggressive and indolent lymphomas, as well as virus-associated and microbe-associated lymphoid diseases, such as those associated with EBV and HIV. He serves on the scientific advisory board of the Lymphoma Research Foundation and on the editorial board of several journals, including Haematologica, Blood, and Leukemia & Lymphoma. Prof. Dunleavy has published over 100 manuscripts and textbook chapters and frequently presents his work nationally and internationally.